MA27417A1 - Utilisation du docetaxel/doxorubicin/cyclophosphamide dans la therapie adjuvante du cancer de sein et de l'ovaire - Google Patents

Utilisation du docetaxel/doxorubicin/cyclophosphamide dans la therapie adjuvante du cancer de sein et de l'ovaire

Info

Publication number
MA27417A1
MA27417A1 MA27924A MA27924A MA27417A1 MA 27417 A1 MA27417 A1 MA 27417A1 MA 27924 A MA27924 A MA 27924A MA 27924 A MA27924 A MA 27924A MA 27417 A1 MA27417 A1 MA 27417A1
Authority
MA
Morocco
Prior art keywords
docetaxel
cyclophosphamide
doxorubicin
ovary
breast cancer
Prior art date
Application number
MA27924A
Other languages
English (en)
Inventor
Hichem Chakroun
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MA27417A1 publication Critical patent/MA27417A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
MA27924A 2002-05-17 2004-11-03 Utilisation du docetaxel/doxorubicin/cyclophosphamide dans la therapie adjuvante du cancer de sein et de l'ovaire MA27417A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38085002P 2002-05-17 2002-05-17

Publications (1)

Publication Number Publication Date
MA27417A1 true MA27417A1 (fr) 2005-07-01

Family

ID=29550025

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27924A MA27417A1 (fr) 2002-05-17 2004-11-03 Utilisation du docetaxel/doxorubicin/cyclophosphamide dans la therapie adjuvante du cancer de sein et de l'ovaire

Country Status (28)

Country Link
US (2) US20040014694A1 (fr)
EP (1) EP1507573A1 (fr)
JP (1) JP4773719B2 (fr)
KR (1) KR20050000544A (fr)
CN (1) CN1652845A (fr)
AU (1) AU2003244646B2 (fr)
BR (1) BR0310026A (fr)
CA (1) CA2486124A1 (fr)
CR (1) CR7575A (fr)
EC (1) ECSP045433A (fr)
HR (1) HRPK20041072B3 (fr)
IL (1) IL165214A0 (fr)
MA (1) MA27417A1 (fr)
ME (2) MEP16308A (fr)
MX (1) MXPA04010640A (fr)
MY (1) MY146533A (fr)
NO (1) NO20045370L (fr)
NZ (1) NZ535992A (fr)
OA (1) OA12819A (fr)
PA (1) PA8574001A1 (fr)
RS (1) RS96304A (fr)
RU (1) RU2321396C2 (fr)
TN (1) TNSN04217A1 (fr)
TW (1) TWI374741B (fr)
UA (1) UA81628C2 (fr)
UY (1) UY27812A1 (fr)
WO (1) WO2003097164A1 (fr)
ZA (1) ZA200408549B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06003222A (es) * 2003-09-25 2006-05-22 Astellas Pharma Inc Agente antitumoral que comprende un inhibidor de histona desacetilasa y un inhibidor de topoisomerasa ii.
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US20080085879A1 (en) * 2006-08-31 2008-04-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating estrogen-responsive conditions by orphan nuclear receptor activation
EP2694056B1 (fr) * 2011-04-01 2019-10-16 AstraZeneca AB Traitement thérapeutique
WO2013079964A1 (fr) 2011-11-30 2013-06-06 Astrazeneca Ab Traitement combiné du cancer
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
WO2014169067A1 (fr) * 2013-04-09 2014-10-16 Merrimack Pharmaceuticals, Inc. Compositions pour améliorer les résultats de la chimiothérapie liposomale
KR20160141857A (ko) * 2014-04-25 2016-12-09 제넨테크, 인크. 트라스투주맙-mcc-dm1 및 퍼투주맙을 이용하는 초기 유방암의 치료방법
WO2016005962A2 (fr) 2014-07-11 2016-01-14 Dr. Reddy’S Laboratories Limited Formulations liquides stables de cyclophosphamide et procédés associés
US10849916B2 (en) 2014-07-11 2020-12-01 Dr. Reddys Laboratories Limited Stable liquid formulations of cyclophosphamide and its impurities
KR102626155B1 (ko) 2015-03-06 2024-01-17 비욘드스프링 파마수티컬스, 인코포레이티드. Ras 돌연변이와 관련된 암의 치료 방법
WO2017068227A1 (fr) * 2015-10-22 2017-04-27 Universidade De Santiago De Compostela Méthodes pour utiliser des régulateurs d'augmentation de l'expression ou d'activation de p53 et/ou des régulateurs de réduction ou inhibiteurs de l'expression de p63-alpha pour le traitement de nafld (stéatose hépatique non alcoolique) et/ou nash (stéatohépatite non alcoolique)
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
WO2018039452A1 (fr) * 2016-08-24 2018-03-01 The Wistar Institute Of Anatomy And Biology Méthodes de traitement de cancers à l'aide d'une chimiothérapie à toxicité réduite
WO2018067575A1 (fr) * 2016-10-03 2018-04-12 Indiana University Research And Technology Corporation Thérapie à base de médicaments en association réduisant la réparation de l'adn associée à la parp-1 et augmentant l'efficacité des agents génotoxiques
EP3565812B1 (fr) 2017-01-06 2023-12-27 Beyondspring Pharmaceuticals, Inc. Composés se liant à la tubuline et leur usage thérapeutique
JP2020514412A (ja) * 2017-02-01 2020-05-21 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 好中球減少症の低減方法
HUE064898T2 (hu) 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
WO2019147615A1 (fr) 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition et procédé pour réduire la thrombocytopénie par l'administration de plinabuline
KR20210048483A (ko) * 2018-06-22 2021-05-03 오하이오 스테이트 이노베이션 파운데이션 디하이드로오로테이트 데하이드로게나제의 억제 방법 및 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US6441026B1 (en) * 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US6262054B1 (en) * 1996-02-01 2001-07-17 Sloan-Kettering Institute Of Cancer Research Combination therapy method for treating breast cancer using edatrexate
US6323205B1 (en) * 1996-07-17 2001-11-27 Sloan-Kettering Institute For Cancer Research Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors
US6541508B2 (en) * 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US20020128228A1 (en) * 2000-12-01 2002-09-12 Wen-Jen Hwu Compositions and methods for the treatment of cancer

Also Published As

Publication number Publication date
NZ535992A (en) 2008-11-28
MY146533A (en) 2012-08-15
MEP16308A (en) 2010-06-10
US20070265213A1 (en) 2007-11-15
US20040014694A1 (en) 2004-01-22
HRPK20041072B3 (en) 2007-07-31
CN1652845A (zh) 2005-08-10
OA12819A (en) 2006-07-10
PA8574001A1 (es) 2003-12-19
MXPA04010640A (es) 2005-08-16
EP1507573A1 (fr) 2005-02-23
TWI374741B (en) 2012-10-21
TNSN04217A1 (en) 2007-03-12
ECSP045433A (es) 2005-01-03
UA81628C2 (uk) 2008-01-25
JP2005529925A (ja) 2005-10-06
CR7575A (es) 2006-05-10
TW200407152A (en) 2004-05-16
UY27812A1 (es) 2003-11-28
NO20045370L (no) 2004-12-08
KR20050000544A (ko) 2005-01-05
JP4773719B2 (ja) 2011-09-14
IL165214A0 (en) 2005-12-18
RU2004136984A (ru) 2005-06-27
WO2003097164A1 (fr) 2003-11-27
ME00055B (me) 2010-10-10
AU2003244646B2 (en) 2008-08-07
HRP20041072A2 (en) 2005-06-30
RS96304A (en) 2006-10-27
AU2003244646A1 (en) 2003-12-02
RU2321396C2 (ru) 2008-04-10
ZA200408549B (en) 2006-01-25
BR0310026A (pt) 2005-02-15
CA2486124A1 (fr) 2003-11-27

Similar Documents

Publication Publication Date Title
MA27417A1 (fr) Utilisation du docetaxel/doxorubicin/cyclophosphamide dans la therapie adjuvante du cancer de sein et de l'ovaire
HUP0600780A2 (en) Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies
HUP0200763A2 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
PL365244A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
IS8127A (is) Aðferðir og samsetningar sem nýta ónæmistemprandiefnasambönd í meðferð og umönnun á krabba og öðrum sjúkdómum
AU2003253877A1 (en) Thermotherapy method for treatment and prevention of breast cancer and cancer in other organs
HK1162948A1 (zh) 哈米特林 衍生物及其在治療癌症中的應用
EP1129217A4 (fr) Compositions et methodes permettant de diagnostiquer et de traiter des maladies
AU2002341566A1 (en) Treatment and prevention of mucositis in cancer patients
HK1074167A1 (en) Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
EP1572741A4 (fr) Agents diagnostiques et therapeutiques
IS6967A (is) Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
AU2002366433A1 (en) Methods and compositions for treating metabolic bone diseases relating to human endokine alpha
EE200300473A (et) Tsüano-asendatud dihüdropürimidiinühendid ja nende kasutamine haiguste raviks
HK1026637A1 (en) Compositions for administering taxanes orally to human patients and their use
EP1420814A4 (fr) Compositions et techniques de therapie et de diagnostic du cancer du sein
PL366066A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
IL162941A0 (en) Carboxamidine derivatives and their use in the treatment of vascular diseases
HUP0200825A2 (en) Compositions and methods for the treatment and diagnosis of breast cancer
FR2825279B1 (fr) Medicament utile dans le traitement du cancer
FI20021617A0 (fi) Diagnostisia ja terapeuttisia menetelmiä
AU2001280443A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
FR2862881B1 (fr) Microdispositif de diagnostic et de therapie in vivo
AU8466601A (en) Methods of screening novel agents for use in cancer therapy and prevention
GB0007754D0 (en) Proteins and their use for diagnosis and treatment of breast cancer